IngredientsAgmatine, also known as 4-aminobutyl-guanidine, was discovered in 1910 by Albrecht Kossel. It is a natural substance formed by the decarboxylation of the amino acid L-arginine and belongs to the broader chemical class of biogenic amines. Agmatine belongs to a group of molecules called biogenic amines (BAs), which includes histamine, tyramine, putrescine, cadaverine, spermidine, and spermine.
The molecular formula is C5H14N4, and agmatine is sometimes referred to by the alternative systematic name 1-(4-aminobutyl)guanidine or decarboxylated arginine. The term "agmatine" stems from A- (for amino-) + g- (from guanidine) + -ma- (from ptomaine) + -in (German)/-ine (English) suffix, with insertion of -t- apparently for euphony. Agmatine is a naturally occurring polyamine derived from arginine via arginine decarboxylase and has been shown to play multifaceted roles in the mammalian body, impacting a wide range of physiological and pathological processes.
Agmatine is a naturally occurring molecule ubiquitously found in nature, biosynthesized by decarboxylation of the amino acid arginine. It is found in low amounts in many foodstuffs derived from plants and fish, with levels as high as 200–650 mg/kg found in certain fish and animal products. In 1910, biochemist Albrecht Kossel at the Heidelberg Academy of Sciences in Germany discovered agmatine in herring roe and reported a synthesis of it. Nine years later, Frederick W. Heyl at Upjohn reported the presence of agmatine in pollen protein extracts from ragweed (Ambrosia artemisiifolia).
High levels of agmatine are present in alcoholic beverages such as wine, beer, and sake, which would seem to confirm the role of yeasts in agmatine production. Normal agmatine fecal concentrations are the highest among amines, at 14.42 μmol/g dry weight. Microbial production of agmatine is therefore considered an important source for absorption of agmatine into the body by the mucosal lining of the large intestine. Although mammals appear to possess only limited capacity to synthesize endogenous agmatine, accumulating evidence suggests that agmatine derived from diet and the gut microbiota contributes to systemic levels of this polyamine.
Agmatine is presently used in the dietary supplement industry in the forms of single administration agmatine and agmatine sulfate. The "sulfate" in "agmatine sulfate" refers to the salt form of agmatine, which improves its stability and bioavailability as a supplement. Supplements are commercially available as oral capsules, loose powders, and occasionally as liquid preparations. Agmatine sulfate is by far the most widely encountered commercial form.
Agmatine, a natural polyamine produced from arginine by arginine decarboxylase, was first discovered in 1910, but its physiological significance was disregarded for a century. Albrecht Kossel was awarded the Nobel Prize in Physiology or Medicine the same year (1910) for his discoveries in cell biology. Interest in the molecule's biological role in mammals was largely dormant until the early 1990s, when researchers began examining it as an endogenous neuromodulator. The recent rediscovery of agmatine as an endogenous ligand for α2-adrenergic and imidazoline receptors in the mammalian brain suggests that this amine may be a promising therapeutic agent for treating a broad spectrum of central nervous system-associated diseases.
In the past two decades, numerous preclinical and several clinical studies have demonstrated its pleiotropic modulatory functions on various molecular targets related to neurotransmission, nitric oxide synthesis, glucose metabolism, polyamine metabolism, and carnitine biosynthesis, indicating potential for therapeutic applications and use as a nutraceutical to improve quality of life.
Agmatine, as a discrete chemical entity, was not identified or named until 1910, and it does not correspond to any specific botanical or herbal preparation with a documented history in traditional medicine systems such as Ayurveda, Traditional Chinese Medicine, or Western herbalism. Unlike many other dietary supplement ingredients, agmatine has no established ethnobotanical tradition of use under its own name or as an isolated compound. Rather, it is present in trace amounts in a wide variety of fermented and protein-rich foods that have been consumed across cultures for millennia, including fermented fish products, wines, beers, and aged meats — foods whose fermentation processes allow microbial arginine decarboxylase activity to generate agmatine naturally.
Several food products contain only small amounts of polyamines, while higher concentrations can be found in fermented foods. Polyamines could also be considered indicators of freshness in fish and meat products, as these moieties are produced during food storage, confirming the main role of microorganisms in their synthesis. Polyamines such as agmatine, putrescine, spermine, and spermidine are considered bioregulators of numerous cell functions, being involved in the process of cell growth, division, and differentiation. These biogenic amines are also involved in tissue repair and intracellular signaling.
Agmatine's emergence as a deliberate dietary supplement ingredient is an entirely modern development, driven by pharmacological and neuroscience research beginning in the 1990s. Its use in this context has no traditional precedent separate from the consumption of foods that incidentally contain it.
Agmatine is a cationic amine formed by decarboxylation of L-arginine by the mitochondrial enzyme arginine decarboxylase (ADC). Agmatine is synthesized in the brain and stored in synaptic vesicles in regionally selective neurons. Agmatine is released by depolarization and is inactivated by agmatinase.
Agmatine degradation occurs mainly by hydrolysis, catalyzed by agmatinase into urea and putrescine, the diamine precursor of polyamine biosynthesis. An alternative pathway, mainly in peripheral tissues, is by diamine oxidase-catalyzed oxidation into agmatine-aldehyde, which is in turn converted by aldehyde dehydrogenase into guanidinobutyrate and secreted by the kidneys.
The enzymatic activity of arginine decarboxylase, which produces agmatine from arginine, is low in mammals, suggesting that a large portion of agmatine is supplemented from diets and gut microbiota. Among gut bacteria, arginine can be converted into agmatine and subsequently putrescine, with these amino acid-dependent pathways highlighting how gut microbial metabolism and dietary intake link to colonic polyamine availability.
Oral agmatine is absorbed from the gastrointestinal tract and readily distributed throughout the body. Rapid elimination from non-brain organs of ingested (un-metabolized) agmatine by the kidneys has indicated a blood half-life of approximately 2 hours. Its ability to cross the blood-brain barrier and its role in neurotransmission processes postulate agmatine as a potential candidate for neuroprotection. Agmatine's pharmacokinetics, including its absorption, distribution, metabolism, and excretion, underscore the complexity of its action and the potential for therapeutic application.
Agmatine itself is the biologically active compound of interest. It exerts its effects not through a single receptor or pathway but through simultaneous engagement with multiple molecular targets, which is characteristic of its classification as a pleiotropic neuromodulator.
Agmatine interacts with nicotinic, imidazoline I1 and I2, α2-adrenergic, glutamate NMDA, and serotonin 5-HT2A and 5-HT3 receptors.
Agmatine inhibits nitric oxide synthase (NOS) and induces the release of some peptide hormones. Agmatine modulates nitric oxide through various mechanisms, stimulating some types of NOS while inhibiting others. Intrathecal administration of agmatine, an NMDA receptor antagonist and nitric oxide synthase inhibitor, prevents neuropathic pain behavior in a dose-dependent manner by acting at the GluN2B subunit of the NMDAr.
Agmatine degradation is catalyzed by agmatinase into urea and putrescine, the diamine precursor of polyamine biosynthesis. Through this pathway, agmatine sits at a critical upstream point in the polyamine biosynthetic cascade. It can also compete with polyamines at their regulatory sites, modulating cellular proliferation and growth signaling.
Agmatine has a positive effect in the central nervous system to counteract excitotoxicity, oxidative stress, inflammation, alteration of the blood-brain barrier, and energy disorders during ischemic events. Multiple interactions within the ischemic cascade show its ability to mitigate free radical formation, attenuate excitotoxicity, modulate inflammatory responses, stabilize the blood-brain barrier, and preserve mitochondrial function.
The neuroprotective properties of agmatine are attributed to its ability to modulate several key pathways implicated in disease pathogenesis, such as inhibition of NMDA receptors, activation of Nrf2, and suppression of the HMGB1/RAGE/TLR4/MyD88/NF-κB signaling cascade. Analysis of the molecular mechanisms of agmatinergic neuroprotection suggested the involvement of proteins central to redox signalling and neuroplasticity, including cAMP-response element binding protein (CREB), brain-derived neurotrophic factor (BDNF), and ERK1/2.
Recent evidence has demonstrated possible fast antidepressant-like actions of agmatine. The antidepressant-like effect of agmatine administered orally to mice subjected to the tail suspension test is dependent on the modulation of molecular targets associated with the fast antidepressant-like effect displayed by ketamine. In particular, the effect involves inhibition of NMDA receptors, since it enhanced the antidepressant potency of MK-801 (an NMDA receptor antagonist) up to 100-fold.
Moreover, the antidepressant-like effect of agmatine is dependent on AMPA and TrkB receptor activation, since administration of an AMPA receptor antagonist or a TrkB receptor antagonist completely abolished its antidepressant-like response. Importantly, these behavioral responses were accompanied by an increase in BDNF, GluA1, and PSD-95 immunocontent in the prefrontal cortex of mice.
The antidepressant-like effect of agmatine is also dependent on phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt)/glycogen synthase kinase-3β/mechanistic target of rapamycin (mTOR) signaling. This signaling pathway parallels the mechanism proposed for ketamine's rapid antidepressant effect.
Enhanced glucose metabolism associated with increased insulin release, and reduced catecholamine release associated with mild reduction in blood pressure and heart rate, are additional effects of agmatine that may be contributory to its salutary effects on the nervous system. The exogenous addition of agmatine also exerts significant effects on glucose metabolism in obese models, as well as cardioprotective effects.
The most clinically advanced area of agmatine research is neuropathic pain. Substantial preclinical evidence and clinical trials have shown that oral agmatine sulfate treatment is safe and effective in reducing neuropathic pain and improving health-related quality of life in lumbar disc-associated radiculopathy (sciatica).
Key Clinical Trial (Keynan et al., 2010): This is the only randomized controlled trial (RCT) of agmatine for pain. It was a two-part study: (a) an open-label dose-escalation safety study in four cohorts (doses 1.335–3.56 g/day for 10–21 days), followed by (b) a randomized, double-blind, placebo-controlled trial in 99 patients with lumbar disc-associated radiculopathy (2.67 g/day for 14 days). The RCT showed significantly greater improvement in pain (26.7% vs. 6.0%, p≤0.05) and quality of life (70.8% vs. 20.0%, p≤0.05) with no treatment-related adverse events. However, the analyzed sample was modest (n=61 completers), the treatment duration was short (14 days), and the study was conducted by investigators with a direct interest in agmatine commercialization.
Small Fiber Neuropathy (Rosenberg et al., 2020, PMC): Peripheral neuropathies associated with painful small fiber neuropathy are complex conditions, resistant to treatment with conventional medications. Previous clinical studies strongly support the use of dietary agmatine as a safe and effective treatment for neuropathic pain. In a small consecutive case series, 11 of 12 recruited patients with painful small-fiber neuropathy completed 2 months of 2.67 grams per day of agmatine sulfate. A concerning caveat of the previous clinical trials was that after the short two-week treatment period, the effectiveness of agmatine treatment gradually dissipated, suggesting that treatment should continue for as long as symptoms persist.
Preclinical Evidence: A large body of in vitro and in vivo experimental evidence has demonstrated the neuroprotective effects of agmatine. This neuroprotective effect has been hypothesized to be related to its ability to block heteromeric NMDA receptor channels. In ex vivo spinal cord dorsal horn, agmatine's attenuation of NMDA-evoked calcium transients was significantly reversed by disruption of the PSD95-nNOS link, indicating that agmatine requires an intact NMDAr-PSD95-nNOS pathway to attenuate NMDA receptor-mediated calcium transients and thermal hyperalgesia.
Evidence Assessment: Human clinical evidence is limited to one small RCT and a case series, both from a narrow group of researchers. The preclinical evidence base is considerably larger and mechanistically coherent. Overall clinical evidence is preliminary but positive; independent large-scale replication is needed.
In the brain, comparable to established neurotransmitters, agmatine acts as a neuromodulator, influencing the regulation, metabolism, and reabsorption of neurotransmitters that are key to mood disorders, learning, cognition, and the management of anxiety and depression.
Human Pilot Study (Shopsin, 2013): Exogenous agmatine was ingested in doses of 2–3 mg/day by depressed subjects with Major Depressive Disorder (MDD), clinically assessed using the 21-item Hamilton Rating Scale for Depression (HAM-D), the Clinical Global Impression (CGI), and the Brief Psychiatric Rating Scale (BPRS). Three depressed subjects showing total illness remission with exogenous agmatine did not relapse after concomitantly adding parachlorophenylalanine (a serotonin-depleting agent). Effective in relieving both psychomotor agitation and retardation, the antidepressant effect was free of physical or behavioural side effects, with gastrointestinal discomfort and loose stools in one subject resolving spontaneously within days. The antidepressant effect of exogenous agmatine was documented in a small number of MDD subjects, and was not reversed by serotonin depletion, confirming findings in animals that therapeutic response is not mediated by serotonergic mechanisms.
Animal and Mechanistic Studies: Chronic treatment with agmatine produced significant antidepressant-like behaviour in the forced swim test and sucrose preference test, as well as anxiolytic-like behaviour, with improved cognitive impairment in the Morris water maze. Furthermore, agmatine administration reduced the levels of acetylcholinesterase and oxidative stress markers. In addition, agmatine treatment significantly increased BDNF levels and inhibited serum corticosterone levels in stressed mice.
Evidence Assessment: Preclinical (animal model) evidence for antidepressant effects is extensive and mechanistically well-characterized. Human clinical evidence consists only of a very small, uncontrolled pilot study (n=3 completers). No large randomized controlled trials in human depression have been published. Evidence strength is preliminary — animal data are compelling, human data are insufficient.
Agmatine, an endogenous cationic amine, exerts a wide range of biological effects, and its role in anxiety has been investigated. The forced swim test and elevated plus maze were used to determine the antidepressant and anxiolytic effects of agmatine. Agmatine decreased immobility time in the forced swim test and increased the time spent in the open arms in the elevated plus maze, as compared with the saline group. Comprehensive behavioral assessments, including the elevated plus maze, open field, dark-light box, social interaction, and novel object recognition tests, revealed that therapeutic agmatine administration (1.0 and 30 mg/kg) significantly reduced induced anxiety-like behaviors, with the higher dose showing more robust and sustained effects across multiple time points.
Evidence Assessment: Evidence for anxiolytic effects is entirely preclinical (rodent studies). No human clinical trials specifically targeting anxiety as a primary outcome have been published. Evidence is animal/in vitro only.
Beyond its neuromodulatory functions, agmatine exhibits protective effects across various cellular and systemic contexts, including neuroprotection, nephroprotection, cardioprotection, and cytoprotection, suggesting broad therapeutic potential.
Excitotoxicity: The neuroprotective effect of agmatine against cell damage caused by NMDA and glutamate was investigated in cultured rat hippocampal neurons. 100 µM agmatine completely abolished the increased LDH levels and prevented neuronal death caused by NMDA or glutamate.
Parkinson's Disease: Agmatine has shown significant potential for neuroprotection in Parkinson's Disease due to its multifaceted biological activities, including antioxidant, anti-inflammatory, and anti-apoptotic effects. This review explores the therapeutic potential in treating PD, focusing on neuroprotective mechanisms and evidence from preclinical studies. Agmatine has been demonstrated to mitigate the neurotoxic effects of rotenone by improving motor function, reducing oxidative stress markers, and decreasing levels of pro-inflammatory cytokines in animal models. However, evaluation of agmatine's therapeutic actions against MPTP-induced PD pathology in vivo has yielded contrasting results.
Agmatine biosynthesis in the nervous system is normally very low, but is greatly increased in response to injury, further implicating agmatine in neuroprotection.
Evidence Assessment: All evidence in this domain is preclinical (cell cultures, rodent models). No human clinical trials examining agmatine for Parkinson's disease or other neurodegenerative conditions have been published. Evidence is animal/in vitro only.
Chronic exposure to opioids induces adaptation of glutamate neurotransmission, which plays a crucial role in addiction. Previous studies have revealed that agmatine attenuates opioid addiction and prevents the adaptation of glutamate neurotransmission in the nucleus accumbens of chronic morphine-treated rats. A growing body of evidence has shown that systemic administration of agmatine enhances opioid analgesia but attenuates opioid-induced tolerance and addiction.
Agmatine is a naturally occurring cationic polyamine that has previously been shown to attenuate the rewarding and psychomotor-sensitizing effects of methamphetamine. Studies have examined the effects of agmatine on the discriminative stimulus and hyperthermic effects of methamphetamine.
Evidence Assessment: Evidence for agmatine's role in attenuating opioid tolerance and drug addiction is well-established in animal models but has not been tested in controlled human clinical trials. Evidence is preclinical only.
Agmatine is an endogenous neurotransmitter that acts on imidazoline I1 and I2 receptors, alpha-2 adrenoceptors, NMDA receptors, and serotonergic receptors, and modulates NOS subtypes. It has neuroprotective, anxiolytic, antidepressant, anticonvulsant, and anti-inflammatory properties and is involved in cognitive functions and withdrawal. The cardiovascular effects of agmatine began to be explored after the hypotensive effect of clonidine, an imidazoline agonist, was demonstrated. A systematic review searched PubMed, Cochrane, and Embase, with 60 studies deemed eligible and included in the analysis.
Agmatine seems to modulate noradrenaline release via imidazoline receptors, reducing sympathetic tone in a way similar to clonidine. Although both agmatine and clonidine decreased blood pressure in anesthetized spontaneously hypertensive rats, agmatine did not antagonize clonidine's blood pressure effect, suggesting that agmatine does not act as a clonidine-displacing substance-like agent.
Evidence Assessment: Cardiovascular evidence is predominantly from preclinical studies (rodent and cell models). A systematic review of 60 preclinical studies exists, but no large-scale human cardiovascular trials have been published. Evidence is preclinical only, mechanistically interesting.
A review focusing on agmatine's beneficial effects summarizes evidence for treating depression, anxiety, neuropathic pain, cognitive decline and learning impairment, dependence on drugs, and metabolic diseases including diabetes and obesity. The exogenous addition of agmatine, a cationic molecule produced through arginine decarboxylation by bacteria and plants, exerts significant effects on glucose metabolism in obese models, as well as cardioprotective effects.
Evidence Assessment: Evidence for glucose-metabolism and anti-obesity effects is exclusively from animal models. No controlled human clinical trials in diabetes or metabolic syndrome have been published. Evidence is animal only.
Nervous system conditions associated with agmatine research include: neurotrauma (e.g., stroke, brain and spinal cord injury, glaucoma), neuropathies and neuropathic pain, opioid analgesia and addiction, neurodegenerative diseases (e.g., Parkinson's disease), mood disorders (e.g., anxiety, depression) and cognitive disorders (e.g., Alzheimer's disease); and conditions involving the kidneys, cardiovascular system, gastrointestinal system, liver, and glucose metabolism.
The following dosages are those specifically reported in cited published studies and should not be construed as recommendations.
The mutagenic and genotoxic effects of agmatine had not been previously reported until relatively recently. A study undertook to assess the safety profile of agmatine using currently accepted in vitro and in vivo mutagenicity and genotoxicity tests. Using the bacterial reverse mutation assay (Ames test), the study found that agmatine sulfate (G-Agmatine®) has no mutagenic effects, and it lacked genotoxic effects as evidenced by the lack of increased frequency of micronucleated polychromatic immature erythrocytes following oral administration in the mouse micronucleus test. It had no clastogenic effects as observed by the in vitro chromosomal aberration test using Chinese Hamster lung cells.
All measurements in the long-term case report remained within normal values and good general health status was sustained throughout the study period, up to 5 years. This case study shows for the first time that the recommended high dosage of agmatine may be consumed for at least 5 years without evidence of any adverse effects, providing significant evidence for the extended long-term safety of a high daily dosage of dietary agmatine.
Small safety studies and genotoxicity screens on specific commercial preparations have not shown mutagenicity or genotoxic effects, but published long-term safety in large cohorts is lacking.
In the RCT by Keynan et al. (2010), the study reported no treatment-related adverse events at the dose of 2.67 g/day for 14 days. In the small depression pilot study, the antidepressant effect was free of physical or behavioural side effects; gastrointestinal discomfort and loose stools in one subject resolved spontaneously within days.
Given agmatine's interaction with imidazoline and α2-adrenergic systems and its reported potentiation of opioid analgesia in animal studies, cautious co-administration with centrally acting agents is warranted. Preclinical data suggest agmatine can potentiate opioid analgesia, which could theoretically allow opioid dose reduction but could also alter opioid effects.
Importantly, most clinical data are short-term (days to weeks to a few months in duration). Long-term safety, effects in pregnancy and lactation, and interactions with many prescription medicines are not comprehensively established.
Although many biological functions have been attributed to polyamines, high levels of these compounds in foodstuffs can have toxicological effects; however, no safe level for the intake of polyamines in a diet has yet been established. This applies to agmatine consumed as a component of food at elevated concentrations (e.g., in certain fermented products), and is a distinct context from controlled supplemental use.
Health conditions that Agmatine may help support.
Agmatine is a decarboxylated arginine metabolite functioning as an endogenous neurotransmitter with preclinical evidence for reducing opioid and alcohol self-administration and tolerance. Multiple animal studies show agmatine inhibits ethanol self-administration via imidazoline I1/I2 receptor mechanisms and reduces opioid tolerance. Preclinical evidence is substantial; human clinical trials for craving remain limited.
Agmatine is a decarboxylation product of arginine studied as a nitric oxide modulator with potential ergogenic effects. It inhibits nitric oxide synthase at high doses while potentially enhancing NO at lower doses, and has been proposed for vasodilation and performance enhancement in pre-workout contexts. Human RCT evidence for athletic performance is limited.
Agmatine is an endogenous neurotransmitter/neuromodulator derived from arginine that regulates multiple neurotransmitter systems in the CNS, including NMDA receptor function, imidazoline receptors, and nitric oxide synthesis. Clinical studies support its role in neuropathic pain and neurological protection.
Agmatine is an endogenous neuromodulator derived from arginine decarboxylation, found in mammalian brain, acting at NMDA glutamate, imidazoline, serotonin 5-HT2A, nicotinic, and alpha-2 adrenergic receptors. It functions as a co-transmitter modulating multiple neurotransmitter systems. Small human trials show antidepressant effects.
Agmatine is the decarboxylation product of L-arginine that acts as an endogenous NOS modulator. It stimulates eNOS by binding imidazoline receptors on endothelial cells while inhibiting iNOS and nNOS, providing isoform-selective NO regulation that distinguishes it from simple NO precursors.
Body systems that Agmatine may help support.
Go back